Evidence map›Paper›PMID 26472453›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2016

Method for Confirming Cytoplasmic Delivery of RNA Aptamers.

David D Dickey, Gregory S Thomas, Justin P Dassie, Paloma H Giangrande

Abstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Structural computational modeling of RNA aptamers.Methods (San Diego, Calif.) · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

David D DickeyDepartment of Internal Medicine, University of Iowa, 375 Newton Rd, 5202 MERF, Iowa City, IA, 52242, USA.
Gregory S ThomasDepartment of Internal Medicine, University of Iowa, 375 Newton Rd, 5202 MERF, Iowa City, IA, 52242, USA.
Justin P DassieDepartment of Internal Medicine, University of Iowa, 375 Newton Rd, 5202 MERF, Iowa City, IA, 52242, USA.
Paloma H GiangrandeDepartment of Internal Medicine, University of Iowa, 375 Newton Rd, 5202 MERF, Iowa City, IA, 52242, USA. paloma-giangrande@uiowa.edu.
University of Iowa · US

Funding

PROGRAM IN HEMOSTASIS AND THROMBOSIS FOR ACADEMICT32HL007344 · NHLBI · UNIVERSITY OF IOWA · PI Anil Kumar Chauhan, Steven R Lentz · 1985 to 2026
$6.5M
Aptamer-siRNA Chimeras Targeting HER2-Positive Breast CancersR01CA138503 · NCI · UNIVERSITY OF IOWA · PI GIANGRANDE, PALOMA HOBAN · 2009 to 2013
$1.5M
Novel Chimeric RNA Aptamer Technology to Treat Head and Neck CancerR21DE019953 · NIDCR · UNIVERSITY OF IOWA · PI GIANGRANDE, PALOMA HOBAN, KLINGELHUTZ, ALOYSIUS JOHN · 2009 to 2010
$410k
NCI NIH HHS R01 CA138503NHLBI NIH HHS T32 HL007344NIDCR NIH HHS R21 DE019953
6 · The paper itself

Abstract

RNA aptamers are single-stranded RNA oligos that represent a powerful emerging technology with potential for treating numerous diseases. More recently, cell-targeted RNA aptamers have been developed for delivering RNA interference (RNAi) modulators (siRNAs and miRNAs) to specific diseased cells (e.g., cancer cells or HIV infected cells) in vitro and in vivo. However, despite initial promising reports, the broad application of this aptamer delivery technology awaits the development of methods that can verify and confirm delivery of aptamers to the cytoplasm of target cells where the RNAi machinery resides. We recently developed a functional assay (RIP assay) to confirm cellular uptake and subsequent cytoplasmic release of an RNA aptamer which binds to a cell surface receptor expressed on prostate cancer cells (PSMA). To assess cytoplasmic delivery, the aptamer was chemically conjugated to saporin, a ribosome inactivating protein toxin that is toxic to cells only when delivered to the cytoplasm (where it inhibits the ribosome) by a cell-targeting ligand (e.g., aptamer). Here, we describe the chemistry used to conjugate the aptamer to saporin and discuss a gel-based method to verify conjugation efficiency. We also detail an in vitro functional assay to confirm that the aptamer retains function following conjugation to saporin and describe a cellular assay to measure aptamer-mediated saporin-induced cytotoxicity.

Indexed as

Antigens, SurfaceAptamers, NucleotideCell LineCytoplasmDrug CarriersGlutamate Carboxypeptidase IIHumansRibosome Inactivating Proteins, Type 1RNA InterferenceSaporinsAntigens, SurfaceAptamers, NucleotideDrug CarriersFOLH1 protein, humanGlutamate Carboxypeptidase IIRibosome Inactivating Proteins, Type 1SaporinsAptamersCytoplasmic deliveryCytotoxicitySaporin

Identifiers

PMID26472453
PMCPMC4826031
OpenAlexW2411480476

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.